^
    Back
    Association details:
    Biomarker:NPM1 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    731 Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

    Published date:
    11/02/2023
    Excerpt:
    Of note, NPM1 mutated patients and ELN 2017 low-risk patients showed a very good outcome (Median OS 24.6 months for NPM1 mutated patients...Our large cohort confirms the efficacy of CPX-351 treatment and suggests that CPX-351 may be beneficial also in NPM1 mutated and ELN 2017 favorable risk patients.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

    Published date:
    11/01/2018
    Excerpt:
    Although subgroup size is small, all patients (100%) with IDH1/2 or NPM1 mutations were responders to CPX-351 (n=12; p<0.001 for IDH1/2 and n=6; p=0.03 for NPM1).
    DOI:
    10.1182/blood-2018-99-117412